QR-koda

Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial

Abstract Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC) to improve rifaximin efficacy. In a...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Gabriela Leite, Ali Rezaie, Walter Morales, Stacy Weitsman, Juliana de Freitas Germano, Gillian M. Barlow, Gonzalo Parodi, Maya L. Pimentel, Maria Jesus Villanueva-Millan, Maritza Sanchez, Sarah Ayyad, Ruchi Mathur, Mark Pimentel
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Nature Portfolio 2024-08-01
Ráidu:Scientific Reports
Fáttát:
Irritable bowel syndrome
Diarrhea-predominant
Rifaximin
N-acetylcysteine
Rat model
Bacterial overgrowth
Liŋkkat:https://doi.org/10.1038/s41598-024-69162-4
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid